Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss 2009 First Quarter Results
29 Avril 2009 - 11:26PM
PR Newswire (US)
Wednesday, May 6, 2009 9:00 a.m. EDT CALGARY, April 29
/PRNewswire-FirstCall/ -- NUCRYST Pharmaceuticals Corp. invites
analysts and investors to participate in a briefing on Wednesday,
May 6, 2009, with David B. Holtz, Interim President & Chief
Executive Officer, and Chief Financial Officer, regarding the
Company's 2009 first quarter results. The briefing, via conference
call, is set for 9:00 a.m. EDT. To participate, please call the
toll-free number 1-800-814-4860. In addition to standard disclosure
over wire services, a news release with the first quarter results
will be posted on the NUCRYST web site prior to the call. To listen
to the call live on the Internet, please go to
http://www.nucryst.com/web_casts.htm. The briefing will be recorded
and available for re-broadcast on demand for seven days by dialing
1-877-289-8525. Callers will need to provide the operator with the
following reservation number: 21305201 followed by the number sign.
An audio file of the call will also be archived on the NUCRYST web
site. About NUCRYST Pharmaceuticals NUCRYST Pharmaceuticals Corp.
(NASDAQ: NCST; TSX: NCS) develops, manufactures and commercializes
medical products that fight infection and inflammation using
SILCRYST(TM), its patented atomically disordered nanocrystalline
silver technology. NUCRYST licensed world-wide rights for
SILCRYST(TM) wound care coating products to Smith & Nephew plc,
which markets these products in over 30 countries under their
Acticoat(TM) trademark. NUCRYST has developed its proprietary
nanocrystalline silver in a powder form, referred to as NPI 32101,
for use in medical devices and as an active pharmaceutical
ingredient. Acticoat(TM) is a trademark of Smith & Nephew plc
SILCRYST(TM) is a trademark of NUCRYST Pharmaceuticals Corp.
DATASOURCE: NUCRYST Pharmaceuticals Corp. CONTACT: David Wills,
Gillian McArdle, Investor Relations, NUCRYST Pharmaceuticals Corp.,
(416) 504-8464,
Copyright